IHC

Adani Group's Stocks, Financials unaffected

Retrieved on: 
Saturday, September 2, 2023

The Adani Group's stocks have rebounded strongly since the release of a short-selling report in January 2023.

Key Points: 
  • The Adani Group's stocks have rebounded strongly since the release of a short-selling report in January 2023.
  • Four of the group's largest companies—Adani Enterprises, Adani Ports, Adani Green, and Adani Power—have gained over 100% from their lows.
  • Adani Ports, the most widely held institutional stock in the Adani portfolio, is now trading above its pre-report price.
  • Importantly, the Adani Group operates within the bounds of the law and under the scrutiny of regulatory authorities in respective jurisdictions.

Adani Group's Stocks, Financials unaffected

Retrieved on: 
Saturday, September 2, 2023

The Adani Group's stocks have rebounded strongly since the release of a short-selling report in January 2023.

Key Points: 
  • The Adani Group's stocks have rebounded strongly since the release of a short-selling report in January 2023.
  • Four of the group's largest companies—Adani Enterprises, Adani Ports, Adani Green, and Adani Power—have gained over 100% from their lows.
  • Adani Ports, the most widely held institutional stock in the Adani portfolio, is now trading above its pre-report price.
  • Importantly, the Adani Group operates within the bounds of the law and under the scrutiny of regulatory authorities in respective jurisdictions.

Multiplex Immunohistochemistry Assays: Exploring Applications & Advantages, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, August 31, 2023

TORONTO, Aug. 31, 2023 /PRNewswire-PRWeb/ -- Immunohistochemistry (IHC) is an indispensable tool for research laboratories by providing spatial context and phenotypic data. Multiplex immunohistochemistry technologies are in the early stages of disrupting legacy assays and revealing previously unknown relationships in all types of tissues.

Key Points: 
  • In this free webinar, understand the advantages of using fluorescence versus brightfield immunohistochemistry (IHC) in your research projects and learn how to utilize the data produced from multiplex immunohistochemistry assays.
  • The featured speaker will discuss appropriate antibodies to use in a multiplex IHC assay, and more.
  • TORONTO, Aug. 31, 2023 /PRNewswire-PRWeb/ -- Immunohistochemistry (IHC) is an indispensable tool for research laboratories by providing spatial context and phenotypic data.
  • Multiplex immunohistochemistry technologies are in the early stages of disrupting legacy assays and revealing previously unknown relationships in all types of tissues.

ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers

Retrieved on: 
Thursday, August 31, 2023

ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Key Points: 
  • ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • The new medicine needs to have shown encouraging preliminary clinical results that demonstrate substantial improvement on a clinically significant endpoint over available medicines.
  • ENHERTU previously received BTDs for three indications in breast cancer, including HER2 low metastatic breast cancer, second-line HER2 positive metastatic breast cancer and later-line HER2 positive metastatic breast cancer.
  • Two additional BTDs for ENHERTU were granted for HER2 (ERBB2) mutant metastatic non-small cell lung cancer (NSCLC) and HER2 positive metastatic gastric cancer.

10x Genomics Surpasses 100 Xenium Analyzer Shipments

Retrieved on: 
Tuesday, August 29, 2023

PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch. The milestone reflects strong customer demand for the Xenium platform, which is increasingly recognized as the best performing system for in situ analysis.

Key Points: 
  • Rapid growth and adoption of Xenium Analyzer demonstrates strength of company's innovation engine, broad commercial reach and operational scale
    PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch.
  • I firmly believe Xenium has the potential to be one of the most transformative technologies in our industry in decades."
  • With the vast majority of the first 100 Xenium shipments already installed, researchers are using the system to successfully analyze a variety of tissues and sample types, including fresh frozen, FFPE and tissue microarrays, and reveal new insights into health and disease.
  • Also in 2024, 10x Genomics expects to launch an in-line protein assay to combine with the RNA assays on the exact same tissue section.

Visiopharm and Boston Cell Standards Announce Partnership to Develop Joint IHC Technology for Magnani-Taylor Regulatory Proposal

Retrieved on: 
Tuesday, August 15, 2023

“The higher proposed assay requirements will raise the quality of IHC testing to ensure accurate results, which will benefit pathologists, oncologists and, ultimately, patients,” said Dr. Steven Bogen, CEO, Boston Cell Standards. “However, aligning IHC laboratory testing globally requires that labs have access to enabling quality assurance tools that, until recently, were not available -- calibration standards and image analysis quantification software to measure the calibrator test results.”

Key Points: 
  • Visiopharm and Boston Cell Standards today announced a partnership to develop a joint technology solution that enables labs to meet key provisions of regulatory changes proposed in a groundbreaking editorial recently published in Archives of Pathology & Laboratory Medicine.
  • If adopted, the proposal would represent a significant shift in the IHC lab regulatory landscape, requiring labs to incorporate rigorous assay control methods and calibration.
  • Modern clinical laboratory quality assurance protocols include reference standards, assay calibration, quantitative controls, and standardized units of measure.
  • Visiopharm developed Qualitopix™, a groundbreaking AI-driven image analysis software for IHC assay control quantification and tracking (Levey-Jennings analysis).

GeneTex Launches PD-L1 Antibody Comprehensively Validated by MS Validated Antibodies GmbH for Immunohistochemistry

Retrieved on: 
Tuesday, June 6, 2023

The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies.

Key Points: 
  • The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies.
  • GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
  • GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC).
  • To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC.

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, August 8, 2023

LAUSANNE, Switzerland, Aug. 08, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter 2023 and provided business updates.

Key Points: 
  • We look forward to keeping you updated on our progress.”
    ZYNLONTA generated net sales of $19.2 million in the second quarter of 2023, representing an 11% increase over the second quarter of 2022.
  • The Company’s partner Sobi completed the first European commercial sale of ZYNLONTA with the launch in Germany in the second quarter of 2023.
  • R&D expenses were $31.9 million for the quarter ended June 30, 2023, compared to $48.5 million for the same quarter in 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss second quarter 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Lunit Presents Groundbreaking Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer

Retrieved on: 
Tuesday, August 1, 2023

SEOUL, South Korea, Aug. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of a groundbreaking study at the ASCO (American Society of Clinical Oncology) Breakthrough conference, to be held from August 3 to August 5 in Yokohama, Japan.

Key Points: 
  • This study showcases the potential of Lunit SCOPE HER2, an AI-powered solution designed to detect HER2 expression profile in detail, to provide valuable insights that can predict treatment response, thereby advancing personalized medicine in mCRC patients.
  • The study employed a higher HER2 cutoff (HER2 3+ higher than 50%) than the standards used in breast and gastric cancers (HER2 3+ higher than 10%).
  • "This groundbreaking study marks a significant milestone for Lunit and reinforces our commitment to advancing personalized medicine in cancer treatment," said Brandon Suh, CEO of Lunit.
  • "The findings from this study demonstrate the potential of Lunit SCOPE HER2 to provide valuable insights in predicting treatment response for HER2-positive metastatic colorectal cancer patients.

Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

Retrieved on: 
Wednesday, July 19, 2023

The CTAs submission follows extensive preclinical studies assessing the safety and efficacy of OTOF-GT and successful manufacturing of the gene therapy Drug Product for the clinical trial.

Key Points: 
  • The CTAs submission follows extensive preclinical studies assessing the safety and efficacy of OTOF-GT and successful manufacturing of the gene therapy Drug Product for the clinical trial.
  • Sensorion’s OTOF-GT dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.
  • Géraldine Honnet, Chief Medical Officer of Sensorion, added: “We are excited to advance OTOF-GT, our first gene therapy program, to the clinic to address unmet medical need in the complex hearing space.
  • Hearing loss caused by mutations of the gene encoding for otoferlin is a debilitating disorder with currently no approved drugs.”